Not a good buy right now: price is extended (RSI_6 95) and sitting just below a key resistance (73.15), which skews near-term risk toward a pullback rather than a clean breakout.
Trend is bullish (SMA_5 > SMA_20 > SMA_200), but momentum looks late-cycle (MACD histogram still >0 but contracting), suggesting upside may be limited without a consolidation.
No fresh catalysts (no news this week) and Intellectia signals are absent, so there’s no high-conviction “buy now” trigger for an impatient entry.
Trend: Bullish structure with moving averages stacked positively (SMA_5 > SMA_20 > SMA_200), indicating an established uptrend.
Momentum: MACD histogram is positive (0.918) but “positively contracting,” often seen when upside momentum is fading after a run.
Overbought: RSI_6 at ~95.1 signals extreme overbought conditions; probability of mean reversion/consolidation is elevated.
Levels: Pivot ~68.09 (first meaningful support). Resistance R1 ~73.15 is immediately overhead; price (post-market ~72.88) is very close, increasing the odds of a stall/rejection.
Pattern-based forward odds: Similar-pattern stats point to slightly negative drift (next day -1.15%, next week -2.14%, next month -0.22%), reinforcing “not an ideal chase here.”
Positive Catalysts
remained positive (+8.19% YoY), which can support longer-term sentiment.
Neutral/Negative Catalysts
increases near-term downside risk from profit-taking.
Net income: 19,869,000,000 (down -11.24% YoY) — profitability declined.
EPS: 2,859.3 (down -11.24% YoY) — earnings power weakened year over year.
Gross margin: 36.25 (down -10.71% YoY) — margin compression is a key negative trend to monitor.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target change data was provided, so recent Wall Street upgrades/downgrades and target revisions cannot be confirmed.
Pros (typical bull view based on provided data): ongoing revenue growth and strong price trend.
Cons (typical bear view based on provided data): declining net income/EPS and margin compression; current price appears technically stretched, reducing risk/reward for new money right now.
Wall Street analysts forecast GRVY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRVY is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast GRVY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRVY is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.